MedPath

Orphenadrine Citrate

ORPHENADRINE CITRATE INJECTION, USP

Approved
Approval ID

56bc8e4a-6771-476d-95e8-e4ef2d869cb2

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 29, 2024

Manufacturers
FDA

Akorn

DUNS: 117693100

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Orphenadrine Citrate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code17478-538
Application NumberANDA040484
Product Classification
M
Marketing Category
C73584
G
Generic Name
Orphenadrine Citrate
Product Specifications
Route of AdministrationINTRAMUSCULAR, INTRAVENOUS
Effective DateJanuary 29, 2024
FDA Product Classification

INGREDIENTS (5)

Orphenadrine CitrateActive
Quantity: 30 mg in 1 mL
Code: X0A40N8I4S
Classification: ACTIB
Sodium MetabisulfiteInactive
Quantity: 2.0 mg in 1 mL
Code: 4VON5FNS3C
Classification: IACT
WaterInactive
Code: 059QF0KO0R
Classification: IACT
Sodium ChlorideInactive
Quantity: 5.8 mg in 1 mL
Code: 451W47IQ8X
Classification: IACT
Sodium HydroxideInactive
Code: 55X04QC32I
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Orphenadrine Citrate - FDA Drug Approval Details